Argo Biopharma to Present Positive Phase I Results of siRNA Therapeutic BW-20805 for HAE at ACAAI 2025
Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced it will present Phase I data for BW-20805 at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting, taking place November 6-10 in Orlando, Florida, USA. https://mma.prnewswire.com/media/2816241/Argo_Biopharmaceutical_Logo.jpg BW-20805 is an investigational siRNA therapy that targets […]